This week, Dr. Randi sits down with Nadeem Moiz, CEO of Revance, for a rare, unfiltered look at how one of aesthetics’ most-watched companies is rewriting its playbook. From the rapid rise of Daxxify to the next generation of RHA® fillers, SkinPen®, and regenerative innovations, Moiz reveals how Revance is building something bigger than products: a connected ecosystem that meets today’s more informed, self-aware patient.
He shares where Revance is doubling down, from science-backed longevity and stackable protocols, to AI-powered insight that’s changing how patients experience care. It’s a story of precision, evolution, and the kind of leadership that doesn’t chase trends, it defines them.
In this episode:
🔹 The Daxxify effect: How a performance-driven neurotoxin is reshaping patient expectations and market momentum
🔹 RHA® with mepivacaine: The subtle advancement improving comfort and precision for every injector
🔹 Regenerative rise: SkinPen®, PRP, and biologic stacks driving the skin health revolution
🔹 Stackable strategies: Smarter, synergistic treatment combinations that deliver real-world results
🔹 The GLP-1 era: Where fillers, biostimulators, and skin rejuvenation fit as body composition shifts
🔹 AI with purpose: How data is powering everything from R&D to patient journeys
🔹 2026 preview: A look at where regenerative science, and Revance, are headed next
It’s the kind of conversation that doesn’t just reflect the future of aesthetics, it helps define it.
Sponsored by NewBeauty 💄
📱 Listen and Watch on Spotify: https://spti.fi/dttTK5m
🎧 Listen Now on Apple: https://dub.sh/i5NrNyZ
Episode FAQ
What is Revance 2.0, and who is leading the company now?
On The Dr. Randi Show, Nadeem Moiz, the newly appointed CEO of Revance, explained that the company now calls itself Revance 2.0. He shared that Revance was previously publicly traded and was acquired in February by Crown Laboratories, where he has been part of the team for almost five years. Nadeem Moiz described Revance as standing for science-based innovation, customer centricity, top of the line products that support positive patient and client outcomes, and strong support for the physicians and providers who use its products. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
What makes Daxxify different from other neuromodulators?
During this episode of The Dr. Randi Show, Nadeem Moiz, CEO of Revance, said Daxxify stands out for its longer duration and for the peptide in its formulation, which he views as a key differentiator. He shared that providers have told the company patients are very happy with the longer duration and describe a nice glow after treatment. Nadeem Moiz noted that awareness of Daxxify is still relatively low and that the brand recently passed 1 million vials in the U.S., which he expects the next million to reach faster. He also said Daxxify is approved in China, Australia, and New Zealand, that Revance is exploring other markets, and that in his view it is the only U.S. manufactured toxin sold in the United States. Individual results vary. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
Why did the RHA Collection filler switch from lidocaine to mepivacaine?
On The Dr. Randi Show, host Dr. Randi Boyette shared that she is allergic to lidocaine, which led to a conversation with Revance CEO Nadeem Moiz about the RHA Collection now using mepivacaine. Nadeem Moiz explained that the RHA Collection is produced by Teoxane and that the research leading up to the switch from lidocaine to mepivacaine was very well received, making it the right direction from a research and development perspective. He said the updated line launched in late August, that early reception has been strong, and that more innovation in the RHA lineup is expected in 2026. This is not medical advice, so please talk with your provider about which filler and anesthetic are right for you.
How does SkinPen microneedling fit alongside injectables and other treatments?
Nadeem Moiz, CEO of Revance, told The Dr. Randi Show that SkinPen falls within what he calls the regenerative vertical of aesthetics, which he sees as a major growth area. He shared that Revance offers three microneedling pens, SkinPen, Evo, and Elite, and that SkinPen is now in its fourth generation. Nadeem Moiz said physicians often pair microneedling with other treatments, such as PRP or BioJuve, a microbiome product he described as first in its category for physician dispensing, and that this pairing of procedures is growing as patients look for treatments that support their own collagen and elastin. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
What trends are shaping the aesthetics and skincare industry right now?
On The Dr. Randi Show, Revance CEO Nadeem Moiz pointed to several trends he is watching. On the aesthetics side, he named regenerative treatments, the impact of GLP-1 medications and the role of fillers, and growing interest in biostimulators. On the skincare side, he highlighted skin health for life, anti-aging, and longevity, noting that people are living longer and, in his words, want to be harmonized, not transformed. Nadeem Moiz and Dr. Randi Boyette also discussed how today’s patients are more educated than ever, often prompted by social media to research treatments and stack or pair procedures. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
How are aesthetic treatments evolving to deliver natural-looking results?
Nadeem Moiz, CEO of Revance, told The Dr. Randi Show that he sees natural-looking results as something the company is already built around rather than a shift. He explained that regenerative procedures like SkinPen microneedling are not overnight transformations but gentle harmonization that relies on the body’s own collagen, elastin, and resurfacing. Nadeem Moiz also mentioned ProGen PRP, used for hair regrowth, skin resurfacing, or paired with SkinPen, and the RHA Collection’s range of low, medium, and high density fillers, adding that results ultimately depend on the practitioner performing the treatment. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
What sets Revance apart in a competitive aesthetics market?
During this episode of The Dr. Randi Show, Revance CEO Nadeem Moiz described several differentiators. He said Revance operates two segments, aesthetics and skincare, and is vertically integrated rather than a pure distributor, with a significant portion of its portfolio designed, developed, and manufactured in the United States. Nadeem Moiz credited Crown Laboratories founder Jeff Bedard with the vision to keep the company vertically integrated, which he said allows it to bring products to market faster using in-house capabilities. He added that customer centricity and being one of the easiest companies to do business with are central to how Revance aims to compete on both product and service. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
How will AI change the medical aesthetics industry?
On The Dr. Randi Show, Revance CEO Nadeem Moiz shared that he sees AI, and generative AI in particular, reshaping aesthetics in two main ways. The first is behind the scenes, in areas like customer service, order fulfillment, procurement, and even research and development for skincare formulations. The second is patient facing, including AI simulators that let people preview a treatment plan in an app before visiting a med spa or dermatology office, as well as tools that guide a consumer from first interest to booking a treatment. Nadeem Moiz noted that AI is advancing so quickly that it is hard to keep up and that the industry is still in the early stages. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
What new aesthetics and skincare innovations is Revance planning for 2026?
Nadeem Moiz, CEO of Revance, told The Dr. Randi Show that the company decides which innovations to pursue based on investing in science and research and on bringing safe and effective products to market. He shared that Revance has regenerative technology coming in 2026, including work around exosomes and autologous exosomes designed to pair with SkinPen microneedling, along with continued filler innovation with Teoxane and further evolution of SkinPen. On the skincare side, Nadeem Moiz highlighted expanded formats for PanOxyl acne treatments, including benzoyl peroxide, salicylic acid, and adapalene gel, as well as plans for Blue Lizard mineral sunscreen, new longevity focused innovation from StriVectin, and more eczema options building on the Sarna brand. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
What is the biggest risk aesthetics companies face over the next few years?
On The Dr. Randi Show, Revance CEO Nadeem Moiz said the biggest challenge for aesthetics companies is deciding how far to push the envelope. He explained that companies have the resources to create many new products, but they must balance change against any potential long-term issues for patients. Nadeem Moiz shared that for Revance, staying on the regenerative path provides natural guardrails that favor gentle, steady enhancements. Looking ahead, he said he hopes providers and patients will see Revance 2.0 as a company that delivers on its promise of science-based products with best in class customer service. This reflects Nadeem Moiz’s personal and professional perspective and is not medical advice.
